Hepatosellüler karsinomada p53 gen tedavisi

Hepatoselüler karsinom malign bir tümör olup morbidite ve mortalitesi yüksektir. Sık infiltrasyon nedeniyle kötü prognoz gösterir. Karaciğer kanseri, viral ve çevresel faktörlerle kombinasyon halinde genetik değişikliklerden kaynaklanmaktadır. p53 mutasyonları, hepatoselüler karsinomada tanımlanan ana genetik değişikliği temsil eder. Bu nedenle, potansiyel bir tedavi olarak p53 gen tedavisi önerilmektedir. P53 tümör süpresör geni, tümör sinyallerindeki apoptotik sinyallerden ve dolayısıyla kontrol edilemeyen çoğalması ve nüksden sorumludur. Hastanın tedavisinde hepatoselüler karsinom tedavisine yeni yaklaşımlar gereklidir.

Anahtar Kelimeler:

gen tedavisi, hepatosellüler karsinoma, karaciğer

P53 gene therapy for hepatocellular carcinoma

Hepatocellular carcinoma is a malignant tumor with a very high morbidity and mortality. It has a poor prognosis due to its common infiltrating. Liver carcinogenesis is driven by genetic alterations in combination with viral and environmental factors. P53 mutations represent main genetic alteration described in hepatocellular carcinoma. Because of this, p53 gene therapy is proposed as a potential treatment. P53 tumour suppressor gene is responsible for apoptotic signals in tumour signals and thus for their uncontrolled proliferation and recurrence. New approaches to hepatocellular carcinoma treatment are needed to improve patient survival.

Keywords:

gene therapy, hepatocellular carcinoma, liver cancer,

PDF

___

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–917.
2. Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011; 253: 453–69.
3. Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I, Nakajo M. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer. 2000; 88: 1574–81.
4. Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery. 1993; 113: 612–8.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020–2.
6. Aravalli RN, Steer CJ, Cressman ENK. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008; 48: 2047–63.
7. Huang S, He X. The role of microRNAs in liver cancer progression. British Journal of Cancer. 2011; 104: 235–40.
8. Nault JC, Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin Liver Dis. 2011; 31: 173-87.
9. Hsia CC, Nakashima Y, Thorgeirsson SS, Harris CC, Minemura M, Momosaki S, Wang NJ, Tabor E. Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma. Oncol Rep. 2000; 7: 353–6.
10. Duan F, Lam MG. Delivery approaches of gene therapy in hepatocellular carcinoma. Anticancer Res. 2013; 33: 4711-8.